Bracco Diagnostics Inc.

Princeton, NJ

UEI
JENQYZRP7NL4
CAGE
05HX5
Primary NAICS
325412 Pharmaceutical Preparation Manufacturing
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • Foreign Owned
  • For Profit Organization
Entity structure
Corporate Entity (Not Tax Exempt)
SAM.gov registration date
Physical address
510 Carnegie Center Dr #300, Princeton, NJ 08540, USA
Website
bracco.com
Founded
1927
Employees
1K-5K
Estimated annual revenue
$1B-$10B
Industry
  1. Health Care
  2. Pharmaceuticals, Biotechnology & Life Sciences
  3. Pharmaceuticals
SIC code
28 Chemical & Allied Products
Profiles

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Contract obligations by fiscal year

Fiscal year Obligated
FY2027 To date $470,695
FY2026 $3,888,890
FY2025 $4,482,243
FY2024 $3,396,563
FY2023 $2,962,324

Top agencies by obligations

Rank Agency Obligated, FY2026–FY2027 Share
1 Department of Veterans Affairs $3,476,575
2 Defense Health Agency $883,010

Contract vehicles

Contract awards

Latest 5 listed here. See the rest on GovTribe.

Similar vendors

About the company

Bracco Diagnostics Inc., a foreign-owned, for-profit diagnostic imaging company headquartered in Princeton, New Jersey, operates as a prime contractor supplying rubidium-82 generators, radiopharmaceuticals, contrast media, and related nuclear medicine equipment to federal healthcare agencies on a full-and-open basis with no set-aside designations. The vendor competes exclusively as a prime (100% of recent awards); it maintains no subcontractor footprint on federal contracts.

Bracco's federal customer base concentrates heavily within the Department of Veterans Affairs health system. The top five funding entities account for 79% of combined potential value across recent awards, dominated by VA Veterans Integrated Service Network 12 (37 awards, $134.9 million combined potential value), VISN 8 (22 awards, $10.5 million), VISN 17 (54 awards, $8.7 million), VISN 1 (19 awards, $7.9 million), and VISN 23 (24 awards, $6 million). The Navy Bureau of Medicine and Surgery (36 awards, $1.1 million) and the Defense Health Agency round out the active customer set. Within the VA, Bracco holds a single-award indefinite delivery contract with VISN 17 valued at $1,735,819.44 through March 2029, structured to procure PET rubidium RB-82 systems and related supplies for advanced cardiac positron emission tomography procedures across multiple VA healthcare facilities.

The vendor's work splits between GSA Schedule vehicles and direct agency contracts. Bracco holds positions on two Federal Supply Schedule contracts—V797P5864X (2,061 task orders, $7.2 million combined potential value) and V797P5261X (100 task orders, $242 thousand)—as well as the GSA Pharmaceuticals and Drugs schedule (83 task orders, $30.5 million combined potential value). Representative recent work includes a $2,795,168.57 delivery order from VISN 1 awarded October 2025 for Cardiogen radiopharmaceutical rubidium generators through September 2030; a $2,319,000.94 purchase order from the Defense Health Agency awarded October 2025 for Cardiogen-82 generators and HeartSee software through September 2030; a $1,770,089.70 purchase order from VISN 17 awarded September 2023 for PET rubidium-82 generators and supplies; and a $1,081,088.03 definitive contract from VISN 22 awarded July 2024 for a rubidium RB-82 generator running through July 2027.

Award activity has remained flat over the past five years—6 awards in 2022 to 8 in 2024—with only 2 recorded awards in 2026 at the date of the source snapshot. Five awards (combined potential value $3.6 million) face ultimate completion within the next twenty-four months and therefore present recompete exposure. The vendor's capability portfolio, grounded in NAICS 325412 (Pharmaceutical Preparation Manufacturing) and PSC 6515 (Medical and Surgical Instruments, Equipment, and Supplies), centers on rubidium-82 generator systems, radiopharmaceutical compounds, diagnostic imaging equipment, and associated software and maintenance services for federal cardiac imaging and nuclear medicine programs. Recent awards also include smaller procurement orders for contrast media (such as Lumason sulfur hexafluoride), infusion systems, and software maintenance contracts with VISN 10, reflecting a diversified but clinically focused product and service footprint within the federal healthcare system.

Quick answers

Is Bracco Diagnostics Inc. registered in SAM.gov?

Yes. Bracco Diagnostics Inc.'s SAM.gov registration is active through April 28, 2027.

Which contract vehicles does Bracco Diagnostics Inc. hold?

Bracco Diagnostics Inc. holds a place on 1 federal contract vehicle: FSS-61-IB.

How much has Bracco Diagnostics Inc. received in federal contracts?

Federal contracts obligated $4,482,243 to Bracco Diagnostics Inc. in fiscal year 2025 and $15,200,715 in fiscal years 2023 through 2027.

How does Bracco Diagnostics Inc. rank among federal contractors?

Bracco Diagnostics Inc. ranked #42 in NAICS 325412, #43 in NAICS 325413 and #55 in NAICS 3254 in FY2025.

What is Bracco Diagnostics Inc.'s most recent federal award?

Bracco Diagnostics Inc.'s most recent federal contract award is Pet rubidium radionuclide generators, infusion hardware, software and accessories (W81K0026FA156), from Medical Command (Army), on October 1, 2026.

On GovTribe

See Bracco Diagnostics Inc.'s full federal record

  • Federal contract awards
  • IDV awards
  • Contract vehicles
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors